Contrast-induced nephropathy (CIN) is acute kidney failure that occurs after exposure to contrast agent. There is no sensitive biomarker to predict the development of CIN. In a retrospective study, we investigated the predictive value of the fibrinogen to albumin ratio (FAR) to determine the risk of CIN in patients (N = 246) who underwent carotid angiography. Contrast-induced nephropathy was defined as a 0.5 mg/dL or 25% increase in serum creatinine levels 48 to 72 hours following exposure to a radiocontrast agent. Patients were grouped according to whether they developed CIN or not, that is, CIN(–) and CIN(+) groups, respectively. Contrast-induced nephropathy developed in 39 (15.8%) of all the patients. The fibrinogen levels, neutrophil to lymphocyte ratio (NLR), and FAR in the CIN (+) group were higher than in the CIN (−) group (P < .001). Multivariate analysis showed that age, diabetes, NLR, platelet–lymphocyte ratio, and FAR were independent risk factors for CIN. The area under the curve (AUC) of FAR was 0.800 for the prediction of CIN, and the best cutoff value was 57.4 with sensitivity, specificity, positive predictive value, and negative predictive value of 74.4%, 60.8%, 26.4%, and 92.7%, respectively. The FAR may be useful as a predictor of CIN.
LindsayJAppleSPinnowEE. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59(3):338–43.
2.
ParfreyPSGriffthsSMBarrettBJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320(3):143–9.
3.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.
4.
MehranRNikolskyE. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;(100):S11–5.
5.
TumlinJStaculFAdamA. CIN consensus working panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):14K–20K.
6.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–71.
7.
FarrugiaA. Albumin usage in clinical medicine: tradition or therapeutic?Transfus Med Rev. 2010;24(1):53–63.
8.
NicholsonJPWolmaransMRParkGR. The role of albumin in critical illness. Br J Anaesth. 2000;85(4):599–610.
9.
ChoiHKimYKimSM. Intravenous albumin for the prevention of contrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease undergoing contrast-enhanced CT. Kidney Res Clin Pract. 2012;31(2):106–11.
10.
DaneshJLewingtonS; Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):2848.
11.
SmithEBThompsonWDCrosbieLStirkCM. Fibrinogen and fibrin in atherogenesis. Eur J Epidemiol. 1992;(8 suppl 1):83–7.
12.
LoweGDFowkesFGDawesJDonnanPTLennieSEHousleyE. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 1993;87(6):1915–20.
13.
TakamatsuSSatohKOsanaiI. Fibrinogen/albumin ratio: a useful indicator of hemorheological abnormalities in observation of cerebrovascular disorders. In: HartmannAHoyerS, eds. Cerebral Blood Flow and Metabolism Measurement. Berlin: Springer-Verlag; 1985:130–5.
14.
SapmazISabaTHaberalCToktamisACakmakMCicekD. Fibrinogen albumin ratio: an intriguing relationship for assessing thrombosis risk and suspicious effect on blood viscosity. Int Cardiovasc Res J. 2011;5:153–4.
15.
CelikIEKurtulADuranM. Elevated serum fibrinogen levels and risk of contrast induced acute kidney injury in patients undergoing a percutaneous coronary intervention for the treatment of acute coronary syndrome. Coron Artery Dis. 2016;27(1):13–8.
16.
MorcosSKThomsenHSWebbJA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.
17.
VeldersMAWallentinLBeckerRC. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the platelet inhibition and patient outcomes trial. Am Heart J. 2015;169(6):879–89.
18.
SunXPLiJZhuWW. Platelet to lymphocyte ratio predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2018;69(1):71–8.
19.
DeLongERDeLongDMClarke-PearsonDL, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
20.
PencinaMJD’AgostinoRBSrSteyerbergEW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.
21.
ParaskevasKIMikhailidisDP. Contrast-induced acute kidney injury in patients undergoing carotid artery stenting: an underestimated issue. Angiology. 2017;68(9):752–6.
22.
DonahueMViscontiGFocaccioA. Acute kidney injury in patients with chronic kidney disease undergoing internal carotid artery stent implantation. JACC Cardiovasc Interv. 2015;8(11):1506–14.
23.
TsaiTTPatelUDChangTI. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
24.
Ali-Hasan-Al-SaeghSMirhosseiniSJGhodratipourZ. Strategies preventing contrast-induced nephropathy after coronary angiography: a comprehensive meta-analysis and systematic review of 125 randomized controlled trials. Angiology. 2017;68(5):389–413.
25.
ChongEPohKKLuQ. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): a multi-centre, randomised, controlled trial. Int J Cardiol. 2015;201:237–42.
26.
ZhanBHuangXJiangLBaoHChengX. Effect of nicorandil administration on preventing contrast-induced nephropathy: a meta-analysis. Angiology. 2018;69(7):568–73.
27.
YangSCFuNKZhangJ. preventive effects of alprostadil against contrast-induced nephropathy inpatients with renal insufficiency undergoing percutaneous coronary intervention. Angiology. 2018;69(5):393–9.
28.
YuanYQiuHHuXY. Risk factors of contrast-induced acute kidney injury in patients undergoing emergency percutaneous coronary intervention. Chin Med J (Engl). 2017;130(1):45–50.
29.
ValappilSPKunjukrishnapillaiSIypeM. Predictors of contrast induced nephropathy and the applicability of the Mehran risk score in high risk patients undergoing coronary angioplasty—a study from a tertiary care center in South India. Indian Heart J. 2018;70(3):399–404.
30.
MendiMAAfsarBOksuzF. Uric acid is a useful tool to predict contrast-induced nephropathy. Angiology. 2017;68(7):627–32.
31.
YuanYQiuHSongL. A new risk factor profile for contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Angiology. 2018;69(6):523–31.
32.
KawataniYKurobeHNakamuraYHoriTKitagawaT. The ratio of contrast medium volume to estimated glomerular filtration rate as a predictor of contrast-induced nephropathy after endovascular aortic repair. J Med Invest. 2018;65(1-2):116–21.
33.
TakahashiEAKallmesDFFlemingCJ. Predictors and outcomes of postcontrast acute kidney injury after endovascular renal artery intervention. J Vasc Interv Radiol. 2017;28(12):1687–92.
34.
GuoXSLinKYLiHL. preprocedural high-sensitivity C-reactive protein predicts contrast-induced nephropathy and long-term outcome after coronary angiography. Angiology. 2017;68(7):614–20.
35.
VelibeyYOzATanikO. Platelet-to-lymphocyte ratio predicts contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2017;68(5):419–27.
36.
BarbieriLVerdoiaMNardinMMarinoPSuryapranataHDe LucaG; Novara Atherosclerosis Study Group (NAS). Gender difference in the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. Angiology. 2017;68(6):542–6.
37.
GillumRFMakucDM. Serum albumin, coronary heart disease, and death. Am Heart J. 1992;123(2):507–13.
38.
SchalkBWVisserMBremmerMAPenninxBWBouterLMDeegDJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol. 2006;164(10):969–77.
39.
OduncuVErkolAKarabayCY. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2013;24(2):88–94.
40.
HartopoABGhariniPPSetiantoBY. Low serum albumin levels and in-hospital adverse outcomes in acute coronary syndrome. Int Heart J. 2010;51(4):221–6.
41.
HeymanSNRosenSKhamaisiMIdeeJMRosenbergerC. Reactive oxygen species and the pathogenesis of radiocontrast induced nephropathy. Invest Radiol. 2010;45(4):188–95.
42.
RocheMRondeauPSinghNRTarnusEBourdonE. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–7.
43.
BourdonEBlacheD. The importance of proteins in defense against oxidation. Antioxid Redox Signal. 2001;3(2):293–311.
44.
DonBRKaysenG. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–7.
45.
LiuYTanNZhouYL. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol. 2012;25(3):332–40.
46.
ZhangWJFreiB. Albumin selectively inhibits TNF alpha induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002;55(4):820–9.
47.
SzabaFMSmileyST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002;99(3):1053–9.
48.
StecJJSilbershatzHToflerGH. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation. 2000;102(14):1634–8.
49.
CartyCLCushmanMJonesD. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study. Thromb Haemost. 2008;99(2):388–95.
50.
ShiYWuYBianCZhangWYangJXuG. Predictive value of serum fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010;37(2):178–83.
51.
NdrepepaGBraunSKingL. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111(6):804–10.
52.
SörensenISusnikNInhesterT. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011;80(10):1035–44.
53.
HoffmannDBijolVKrishnamoorthyA. Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am J Pathol. 2012;181(3):818–28.
54.
MosessonMW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–904.
55.
MuratSNKurtulAYarliogluesM. Impact of serum albumin levels on contrast induced acute kidney injury in patients with acute coronary syndromes treated with percutaneous coronary intervention. Angiology. 2015;66(8):732–7.
56.
KarahanOYavuzCKankilicN. Simple blood tests as predictive markers of disease severity and clinical condition in patients with venous insufficiency. Blood Coagul Fibrinolysis. 2016;27(6):684–90.
57.
KarahanOAcetHErtaşF. The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Am J Emerg Med. 2016;34(6):1037–42.
